CUV 0.88% $13.70 clinuvel pharmaceuticals limited

Ssilverchair, page-6

  1. 17,214 Posts.
    lightbulb Created with Sketch. 4690
    Not at all, people with Vitiligo have very little to help them. The initial results seen from Scenesse are phenomenal, I see no reason not to expect fantastic P3 results and quick approval for vitiligo. The phase three trial will be completed quite fast, they're actively recruiting now so I'd be expecting updates soon. First patient in the trial was treated in October of last year... commercialisation is close imo

    More data from the XP trials should come soon as well, not that XP is a very large market (still an additional market for CUV to be a monopoly player in), but most importantly the data will help prove the importance of this drug in sun protection etc
    Last edited by TheAnalyst007: 22/05/24
 
watchlist Created with Sketch. Add CUV (ASX) to my watchlist
(20min delay)
Last
$13.70
Change
0.120(0.88%)
Mkt cap ! $685.8M
Open High Low Value Volume
$13.53 $13.76 $13.42 $747.9K 54.81K

Buyers (Bids)

No. Vol. Price($)
1 233 $13.64
 

Sellers (Offers)

Price($) Vol. No.
$13.71 19 1
View Market Depth
Last trade - 16.10pm 08/11/2024 (20 minute delay) ?
CUV (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.